|
|
|
|
|
by tallanvor
1689 days ago
|
|
Well, no. It appears that the FDA became aware of companies marketing N-acetyl-L-cysteine as a hangover remedy and started the process of taking action at that point. And once they start taking action, they can't ignore some off-label uses for something that's considered a drug. And while this action started in the middle of 2020, there's no evidence that this decision had anything to do with research around the drug and COVID. An example letter sent by the FDA in July 2020: https://www.fda.gov/inspections-compliance-enforcement-and-c... |
|